Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision: v3.4.1 label is added to the page footer, and Revision: v3.4.0 label is removed.SummaryDifference0.0%

- Check32 days agoChange DetectedGlossary toggle options were added (Show glossary/Hide glossary) and the page revision updated from v3.3.4 to v3.4.0 with related Last Update metadata changes; these are minor UI/metadata changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check40 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; this is an administrative update with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded a new 2025 Blood Advances publication on risk stratification of low-dose cytarabine and venetoclax in AML ineligible for intensive chemotherapy; updated author designation for the related Blood Advances citation.SummaryDifference0.0%

- Check68 days agoChange DetectedLocations section now includes numerous new study sites across multiple countries and regions (e.g., Florida, Kentucky, Brussels, Tokyo, Buenos Aires, etc.), with several prior sites removed, altering where participants can enroll.SummaryDifference2%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.